UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 10,991 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 18.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,826 shares of the company's stock after buying an additional 10,991 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.18% of Tarsus Pharmaceuticals worth $3,866,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Paradigm Biocapital Advisors LP increased its position in shares of Tarsus Pharmaceuticals by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company's stock worth $140,191,000 after buying an additional 91,451 shares during the period. Vanguard Group Inc. boosted its position in Tarsus Pharmaceuticals by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company's stock valued at $117,117,000 after acquiring an additional 17,839 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $105,714,000. Lord Abbett & CO. LLC grew its holdings in Tarsus Pharmaceuticals by 115.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after acquiring an additional 685,111 shares during the period. Finally, Invesco Ltd. raised its position in shares of Tarsus Pharmaceuticals by 36.7% in the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after acquiring an additional 250,018 shares in the last quarter. Institutional investors own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 2,315 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the sale, the insider now directly owns 50,751 shares of the company's stock, valued at $2,349,263.79. This represents a 4.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bobak R. Azamian sold 8,534 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $427,638.74. Following the transaction, the chief executive officer now directly owns 53,635 shares in the company, valued at approximately $2,687,649.85. The trade was a 13.73% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,542 shares of company stock valued at $1,581,173. Corporate insiders own 8.97% of the company's stock.

Tarsus Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ TARS traded down $0.16 during midday trading on Friday, hitting $43.92. 625,505 shares of the stock traded hands, compared to its average volume of 703,841. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The business has a 50 day moving average price of $46.22 and a two-hundred day moving average price of $48.88. The company has a market cap of $1.85 billion, a PE ratio of -11.53 and a beta of 0.83.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on TARS shares. Jefferies Financial Group upped their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $66.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.